Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Bracci

Showing results (21-30 of 37) with videos related to

Pageof 4
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 9, 2008
Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require Toll-like receptor triggeringLaura Bracci, Reto Schumacher, Maurizio Provenzano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltrationLaura Bracci, Federica Moschella, Paola Sestili, et al.
Journal of Translational Medicine|November 14, 2006
Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donorsMaurizio Provenzano, Laura Bracci, Stephen Wyler, et al.
Journal of Cellular and Molecular Medicine|July 17, 2009
A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificitiesMaurizio Provenzano, Giovanni Sais, Laura Bracci, et al.
Cancer Research|December 16, 2010
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosisGiovanna Schiavoni, Antonella Sistigu, Mara Valentini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 22, 2002
Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine modelEnrico Proietti, Laura Bracci, Simona Puzelli, et al.
Cells|April 16, 2020
Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis BlockadeAlessandra Rossi, Valeria Lucarini, Iole Macchia, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patientsRachel Rosenthal, Célia Groeper, Laura Bracci, et al.
Cells|April 30, 2021
Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor ModelsMaria Ciccolella, Sara Andreone, Jacopo Mancini, et al.
Trials|September 4, 2021
Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trialEleonora Aricò, Luciano Castiello, Laura Bracci, et al.
Pageof 4

Showing results (21-30 of 37) with videos related to

Sort By:
Pageof 4
Journal of Immunotherapy (Hagerstown, Md. : 1997)|May 9, 2008
Efficient stimulation of T cell responses by human IFN-alpha-induced dendritic cells does not require Toll-like receptor triggeringLaura Bracci, Reto Schumacher, Maurizio Provenzano, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2007
Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltrationLaura Bracci, Federica Moschella, Paola Sestili, et al.
Journal of Translational Medicine|November 14, 2006
Characterization of highly frequent epitope-specific CD45RA+/CCR7+/- T lymphocyte responses against p53-binding domains of the human polyomavirus BK large tumor antigen in HLA-A*0201+ BKV-seropositive donorsMaurizio Provenzano, Laura Bracci, Stephen Wyler, et al.
Journal of Cellular and Molecular Medicine|July 17, 2009
A HCMV pp65 polypeptide promotes the expansion of CD4+ and CD8+ T cells across a wide range of HLA specificitiesMaurizio Provenzano, Giovanni Sais, Laura Bracci, et al.
Cancer Research|December 16, 2010
Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosisGiovanna Schiavoni, Antonella Sistigu, Mara Valentini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|June 22, 2002
Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine modelEnrico Proietti, Laura Bracci, Simona Puzelli, et al.
Cells|April 16, 2020
Tumor-Intrinsic or Drug-Induced Immunogenicity Dictates the Therapeutic Success of the PD1/PDL Axis BlockadeAlessandra Rossi, Valeria Lucarini, Iole Macchia, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 27, 2009
Differential responsiveness to IL-2, IL-7, and IL-15 common receptor gamma chain cytokines by antigen-specific peripheral blood naive or memory cytotoxic CD8+ T cells from healthy donors and melanoma patientsRachel Rosenthal, Célia Groeper, Laura Bracci, et al.
Cells|April 30, 2021
Anticancer Effects of Sublingual Type I IFN in Combination with Chemotherapy in Implantable and Spontaneous Tumor ModelsMaria Ciccolella, Sara Andreone, Jacopo Mancini, et al.
Trials|September 4, 2021
Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trialEleonora Aricò, Luciano Castiello, Laura Bracci, et al.
Pageof 4